DLB insider files Form 144 to sell 7,273 common shares

An insider associated with DLB has filed a Form 144 notice to sell 7,273 shares of common stock through Morgan Stanley Smith Barney LLC on or about 12/11/2025 on the NYSE, with an indicated aggregate market value of $500,018.75.

Accepted by SEC EDGAR 12/11/2025 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

An insider associated with DLB has filed a Form 144 notice to sell 7,273 shares of common stock through Morgan Stanley Smith Barney LLC on or about 12/11/2025 on the NYSE, with an indicated aggregate market value of $500,018.75. These shares were originally acquired as restricted stock from the issuer in three grants dated 08/10/2014, 12/15/2016, and 12/15/2018.

The notice also reports that 6,164 common shares were sold on 11/20/2025 for gross proceeds of $407,563.68. Shares of the issuer’s common stock outstanding were 60,845,846 as of the data shown; this is a baseline figure, not the amount being sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for DLB disclose?

The Form 144 discloses that an insider plans to sell 7,273 shares of DLB common stock on or about 12/11/2025 on the NYSE, with an indicated aggregate market value of $500,018.75.

How many DLB shares are planned to be sold and through which broker?

The filing indicates a planned sale of 7,273 common shares of DLB through Morgan Stanley Smith Barney LLC Executive Financial Services.

How and when were the DLB shares being sold originally acquired?

The shares were acquired as restricted stock from the issuer in three tranches: 383 shares on 08/10/2014, 2,148 shares on 12/15/2016, and 4,742 shares on 12/15/2018.

Has the DLB insider sold any shares in the past three months?

Yes. The filing reports that John Couling sold 6,164 DLB common shares on 11/20/2025, generating gross proceeds of $407,563.68.

How many DLB shares were outstanding according to the Form 144 data?

The Form 144 information shows that 60,845,846 shares of DLB common stock were outstanding as of the referenced data, which is provided as a baseline share count.

What representation does the seller make in the DLB Form 144 notice?

By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001894052
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	DOLBY LABORATORIES, INC.
SEC File Number	001-32431
Address of Issuer	1275 Market Street San Francisco CALIFORNIA 94103-1410
Phone	(415) 558-0200
Name of Person for Whose Account the Securities are To Be Sold	JOHN COULING
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7273	500018.75	60845846	12/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/15/2016	Restricted Stock	ISSUER			2148	12/15/2016	Not Applicable
Common	08/10/2014	Restricted Stock	ISSUER			383	08/10/2014	Not Applicable
Common	12/15/2018	Restricted Stock	ISSUER			4742	12/15/2018	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JOHN COULING 1275 Market Street San Francisco CA 94103-1410	Common	11/20/2025	6164	407563.68

144: Remarks and Signature

Remarks
Date of Notice	12/11/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ John David Couling
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)